BioLife Solutions Inc (BLFS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioLife Solutions Inc (BLFS) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-491.00K) by net assets ($372.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can BioLife Solutions Inc fund operations to measure how many days the company can operate on defensive assets alone.
BioLife Solutions Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how BioLife Solutions Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioLife Solutions Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLife Solutions Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SK ETERNIX CO LT
KO:475150
|
0.497x |
|
Henan Zhongyuan Expressway Co Ltd
SHG:600020
|
0.063x |
|
Amore Group
KO:002790
|
0.032x |
|
Guobang Pharma Ltd
SHG:605507
|
0.036x |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
0.278x |
|
Advtech
JSE:ADH
|
0.311x |
|
Beijing Creative Distribution Automation Co Ltd
SHE:002350
|
0.034x |
|
ATAI Life Sciences NV
XETRA:9VC
|
-0.145x |
Annual Cash Flow Conversion Efficiency for BioLife Solutions Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of BioLife Solutions Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see BioLife Solutions Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $371.89 Million | $20.11 Million | 0.054x | +123.84% |
| 2024-12-31 | $348.91 Million | $8.43 Million | 0.024x | +165.28% |
| 2023-12-31 | $337.66 Million | $-12.50 Million | -0.037x | -58.79% |
| 2022-12-31 | $364.19 Million | $-8.49 Million | -0.023x | -129.61% |
| 2021-12-31 | $476.37 Million | $-4.84 Million | -0.010x | -131.98% |
| 2020-12-31 | $205.25 Million | $6.51 Million | 0.032x | +117.27% |
| 2019-12-31 | $83.03 Million | $1.21 Million | 0.015x | -73.15% |
| 2018-12-31 | $43.15 Million | $2.35 Million | 0.054x | -9.23% |
| 2017-12-31 | $10.09 Million | $605.00K | 0.060x | +104.39% |
| 2016-12-31 | $3.17 Million | $-4.33 Million | -1.367x | -170.91% |
| 2015-12-31 | $9.86 Million | $-4.97 Million | -0.504x | -122.32% |
| 2014-12-31 | $13.94 Million | $-3.16 Million | -0.227x | -1962.55% |
| 2013-12-31 | $-13.27 Million | $146.01K | -0.011x | +83.93% |
| 2012-12-31 | $-12.49 Million | $854.93K | -0.068x | -177.33% |
| 2011-12-31 | $-11.18 Million | $-989.92K | 0.089x | -32.50% |
| 2010-12-31 | $-9.55 Million | $-1.25 Million | 0.131x | -57.46% |
| 2009-12-31 | $-7.83 Million | $-2.41 Million | 0.308x | -24.55% |
| 2008-12-31 | $-5.17 Million | $-2.11 Million | 0.409x | -62.74% |
| 2007-12-31 | $-2.47 Million | $-2.71 Million | 1.097x | +127.74% |
| 2006-12-31 | $180.09K | $-712.20K | -3.955x | +73.60% |
| 2005-12-31 | $38.48K | $-576.33K | -14.977x | -1882.23% |
| 2004-12-31 | $612.96K | $515.10K | 0.840x | +233.41% |
| 2003-12-31 | $1.36 Million | $-854.23K | -0.630x | -113.04% |
| 2002-12-31 | $-554.25K | $-2.68 Million | 4.831x | +156.81% |
| 2001-12-31 | $310.77K | $-2.64 Million | -8.504x | -964.52% |
| 2000-12-31 | $3.63 Million | $-2.90 Million | -0.799x | -145.54% |
| 1999-12-31 | $818.40K | $-266.26K | -0.325x | -1699.60% |
| 1998-12-31 | $1.43 Million | $29.12K | 0.020x | +103.35% |
| 1997-12-31 | $2.46 Million | $-1.49 Million | -0.608x | -17.07% |
| 1996-12-31 | $3.99 Million | $-2.07 Million | -0.519x | -34.00% |
| 1995-12-31 | $3.98 Million | $-1.54 Million | -0.387x | 0.00% |
| 1994-12-31 | $3.98 Million | $-1.54 Million | -0.387x | +21.05% |
| 1993-12-31 | $5.30 Million | $-2.60 Million | -0.491x | +67.30% |
| 1992-12-31 | $5.60 Million | $-8.40 Million | -1.500x | -318.60% |
| 1991-12-31 | $12.00 Million | $-4.30 Million | -0.358x | +21.17% |
| 1990-12-31 | $5.50 Million | $-2.50 Million | -0.455x | -15.38% |
| 1989-12-31 | $3.30 Million | $-1.30 Million | -0.394x | -- |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more